Avalon GloboCare Corp. is a clinical-stage biotechnology company. It involved in developing and delivering innovative, transformative cellular therapeutics, precision diagnostics and clinical laboratory services. Avalon GloboCare Corp. is based in FREEHOLD, N.J.
| Revenue (Most Recent Fiscal Year) | $1.26M |
| Net Income (Most Recent Fiscal Year) | $-18.26M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -28775.85% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -74.36% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.38 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.38 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-3.77 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Real Estate |
| Industry | Real Estate Services |
| Common Shares Outstanding | 12.05M |
| Free Float | 9.13M |
| Market Capitalization | $4.49M |
| Average Volume (Last 20 Days) | 0.27M |
| Beta (Past 60 Months) | -0.06 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 24.19% |
| Percentage Held By Institutions (Latest 13F Reports) | 1.42% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |